Clinical Trial Update: Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sipuleucel-T (Provenge) followed by docetaxel in castration-resistant prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• PROVENGE (sipuleucel-T)

Snippet

Sponsor: The University of Texas Health Science Center, Houston | Conditions: Prostate Cancer | Phase 2 | Status: WITHDRAWN